Connecticut Could Permit Stronger Cannabis Products with High-Potency Label
Connecticut cannabis high-potency labeling is proposed to permit stronger THC products. This change impacts clinical counseling on potency-related risks. Clinicians must stay informed to advise patients safely.
Cannabis Clinical Research Digest March 2026 | CEDclinic
The Cannabis Clinical Research Digest March 2026 presents 230 items curated for clinical relevance. This digest offers healthcare providers insights into cannabis research and clinical updates. It is an essential resource for clinicians supporting…
Are Hemp-Derived Drinks Here To Stay? – Beverage Information Group
Hemp-derived beverage regulations are evolving rapidly, impacting clinical counseling and patient safety. Understanding the 10 mg THC limit per serving is crucial for clinicians. These regulations address dosing, labeling, and potential drug interactions…
Tennessee Regulators Find Over 650 Unlicensed Hemp Cannabinoid Sellers
Tennessee regulators have found more than 650 unlicensed hemp cannabinoid product sellers operating in the state. This unregulated market poses significant safety risks due to unknown potency and contaminants. Clinicians should be aware of these…
Court Grants Dismissal of THC Potency Action – Law360 Analysis
The court's dismissal of cannabis THC potency limits challenges leaves regulatory authority with state agencies. Clinicians must counsel patients on high potency cannabis risks. Understanding cannabis THC potency limits is essential for safe clinical…
How Growing Cannabis Use is Changing Clinical Treatment Approaches
Changing cannabis use patterns are reshaping clinical treatment approaches. Clinicians must update diagnostic protocols to address evolving potency and consumption methods. Understanding these changes is essential for effective cannabis use disorder…
US Farmers Face Challenges Amid Hemp THC Ban Uncertainty
Hemp THC regulations impact farmers by creating uncertainty in cultivation and processing decisions. This disruption affects the supply chain for hemp-derived cannabinoids. Patients and clinicians must navigate potential product inconsistencies and…
Evil Kermit
When your patient asks if cannabis will cure their condition versus when you explain the actual evidence for symptom management. The difference between hope and realistic therapeutic goals. Further Reading Research DigestAM Policy Update: March 16, 2026…
‘An Attempt To Ban the Industry’: Dallas THC Shops React to Smokable Hemp Rule
Smokable hemp regulatory challenges in Dallas highlight tensions between evolving cannabis laws and patient safety. THCa hemp products convert to intoxicating delta-9 THC, complicating clinical understanding. Clinicians must navigate these challenges to…
What kind of tree is this?
Your dispensary’s favorite diagnostic question: pretty sure that’s an indica, sativa, or hybrid, but honestly the cannabinoid profile matters more than the botanical taxonomy. Via r/trees Further Reading Cannabis Policy WirePolicy Watch: 20…
